Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

NCT ID: NCT00660036

Last Updated: 2016-01-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-09-30
• Study Completion Date: 2011-04-30

Brief Summary

The purpose of this study is to investigate the combination of gemtuzumab ozogamicin, mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia.

Detailed Description

The combination of mitoxantrone and etoposide is an active regimen in refractory/relapsed AML patients. In order to improve the efficacy of mitoxantrone and etoposide as second line therapy in patients with AML we proposed to conduct a phase I/II clinical trial combining gemtuzumab ozogamicin with mitoxantrone and etoposide. The phase I portion of the trial will determine the maximum tolerated dose of gemtuzumab ozogamicin combined with mitoxantrone and etoposide and the phase II portion of the trial will determine the efficacy and safety of the combined regimen in patients with AML.

Conditions

Acute Myeloid Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Gemtuzumab ozogamicin/Mitoxantrone/Etoposide

Group Type: EXPERIMENTAL

Gemtuzumab ozogamicin

Intervention Type: DRUG

On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m\^2, 6 mg/m\^2 or 9 mg/m\^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.

Mitoxantrone

Intervention Type: DRUG

On Days 1-3 of an inpatient hospital stay: 10 mg/m\^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes

Etoposide

Intervention Type: DRUG

On Days 1-5 of an inpatient hospital stay: 100 mg/m\^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours

Interventions

Gemtuzumab ozogamicin

On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m\^2, 6 mg/m\^2 or 9 mg/m\^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.

Intervention Type: DRUG

Mitoxantrone

On Days 1-3 of an inpatient hospital stay: 10 mg/m\^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes

Intervention Type: DRUG

Etoposide

On Days 1-5 of an inpatient hospital stay: 100 mg/m\^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours

Intervention Type: DRUG

Other Intervention Names

Mylotarg®; Novantrone®; ToposarTM

Eligibility Criteria

Inclusion Criteria

• Able to understand and have the ability to provide written consent
• Between 18 and 70 years of age
• Patients with CD33 positive (determined as CD33 expression in ≥ 20% of leukemic blasts) de novo AML that did not respond to first line induction therapy
• ECOG Performance Status of 0-2
• Patients must have the following laboratory values within 48 hours prior to beginning protocol treatment: Serum creatinine ≤ 1.5 mg/ml and calculated creatinine clearance ≥ 50mL/min (using the Cockcroft-Gault equation); AST ≤ 59 IU/L; ALT ≤ 72 IU/L; Total bilirubin ≤ 1.3 mg/ml; Note: Hematologic abnormalities will not be used as a criteria for entry or exclusion.
• Patients must have left ventricular ejection fraction (LVEF) ≥50%
• Females of child-bearing potential must have a negative pregnancy test during screening and all subjects must agree to use an effective method of contraception.

Exclusion Criteria

• Patients with acute promyelocytic leukemia
• Prior use of mitoxantrone or etoposide or gemtuzumab ozogamicin
• Antecedent hematologic disorder preceding initial presentation of AML or therapy related AML
• History of thromboembolic event within the past 12 months
• Hepatitis B or C or HIV positive serology
• Symptomatic central nervous system (CNS) involvement
• History of congestive heart failure
• Myocardial infarction in the past 6 months
• Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
• History of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent
• Patient may not be receiving any other anti neoplastic investigational agents
• INR> 1.5 or patient is receiving systemic anticoagulation (e.g warfarin)
• Patient undergone autologous or allogeneic stem cell transplantation
• Other active malignancies except for non-melanoma skin cancer or cervical intraepithelial neoplasia
• Women who are pregnant or breastfeeding.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Pittsburgh

OTHER

Sponsor Role: lead

Responsible Party

Michael Boyiadzis

PI

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Michael Boyiadzis, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

University of Pittsburgh Cancer Institute / Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Countries

United States

Other Identifiers

07-154

Identifier Type: -

Identifier Source: org_study_id